<?xml version='1.0' encoding='utf-8'?>
<document id="17971660"><sentence text="An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure." /><sentence text="Helicobacter pylori infects over 50% of the worldwide population" /><sentence text=" For eradication, European, Canadian, and American guidelines recommend a regimen consisting of a proton pump inhibitor, clarithromycin, and metronidazole or amoxicillin dosed twice daily for at least 7 days"><entity charOffset="121-135" id="DDI-PubMed.17971660.s3.e0" text="clarithromycin" /><entity charOffset="141-154" id="DDI-PubMed.17971660.s3.e1" text="metronidazole" /><entity charOffset="158-169" id="DDI-PubMed.17971660.s3.e2" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.17971660.s3.e0" e2="DDI-PubMed.17971660.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17971660.s3.e0" e2="DDI-PubMed.17971660.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s3.e0" e2="DDI-PubMed.17971660.s3.e2" /><pair ddi="false" e1="DDI-PubMed.17971660.s3.e1" e2="DDI-PubMed.17971660.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s3.e1" e2="DDI-PubMed.17971660.s3.e2" /></sentence><sentence text=" When this treatment strategy fails, a complex, multidosed bismuth-based quadruple regimen is recommended" /><sentence text=" Unfortunately, for patients with heart failure, this salvage regimen can be potentially hazardous due to the drug-drug interaction with tetracycline and digoxin, as well as the large salicylate content with bismuth subsalicylate"><entity charOffset="137-149" id="DDI-PubMed.17971660.s5.e0" text="tetracycline" /><entity charOffset="154-161" id="DDI-PubMed.17971660.s5.e1" text="digoxin" /><entity charOffset="184-194" id="DDI-PubMed.17971660.s5.e2" text="salicylate" /><entity charOffset="208-229" id="DDI-PubMed.17971660.s5.e3" text="bismuth subsalicylate" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e0" e2="DDI-PubMed.17971660.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e0" e2="DDI-PubMed.17971660.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e0" e2="DDI-PubMed.17971660.s5.e2" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e0" e2="DDI-PubMed.17971660.s5.e3" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e1" e2="DDI-PubMed.17971660.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e1" e2="DDI-PubMed.17971660.s5.e2" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e1" e2="DDI-PubMed.17971660.s5.e3" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e2" e2="DDI-PubMed.17971660.s5.e2" /><pair ddi="false" e1="DDI-PubMed.17971660.s5.e2" e2="DDI-PubMed.17971660.s5.e3" /></sentence><sentence text=" As H" /><sentence text=" pylori infection is so prevalent, providers will most likely encounter such a therapeutic dilemma" /><sentence text=" A safe, effective, and simplistic alternative is a 10-day fluoroquinolone-based regimen consisting of a proton pump inhibitor, levofloxacin and either clarithromycin or amoxicillin"><entity charOffset="128-140" id="DDI-PubMed.17971660.s8.e0" text="levofloxacin" /><entity charOffset="152-166" id="DDI-PubMed.17971660.s8.e1" text="clarithromycin" /><entity charOffset="170-181" id="DDI-PubMed.17971660.s8.e2" text="amoxicillin" /><pair ddi="false" e1="DDI-PubMed.17971660.s8.e0" e2="DDI-PubMed.17971660.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17971660.s8.e0" e2="DDI-PubMed.17971660.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s8.e0" e2="DDI-PubMed.17971660.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17971660.s8.e1" e2="DDI-PubMed.17971660.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17971660.s8.e1" e2="DDI-PubMed.17971660.s8.e2" /></sentence><sentence text=" Levofloxacin demonstrates excellent bioavailability, widespread tissue and fluid distribution, extended half-life, limited drug interaction profile, low incidence of side effects, and remarkable activity against H"><entity charOffset="1-13" id="DDI-PubMed.17971660.s9.e0" text="Levofloxacin" /></sentence><sentence text=" pylori with minimal primary resistance" /><sentence text=" Compared to the 7-day quadruple regimen, a 10-day levofloxacin-based regimen demonstrated a greater eradication rate, better tolerability, and a lower rate of therapy discontinuation"><entity charOffset="51-63" id="DDI-PubMed.17971660.s11.e0" text="levofloxacin" /></sentence><sentence text=" We briefly provide a summary of the data regarding this levofloxacin-based regimen and two successful cases from our heart failure clinic"><entity charOffset="57-69" id="DDI-PubMed.17971660.s12.e0" text="levofloxacin" /></sentence><sentence text="" /></document>